News from alligator bioscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

02:28 ET Alligator Bioscience AB (publ): Interim report January-September 2020

Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented interim...


01:23 ET Alligator Bioscience focuses on ATOR-1017 and mitazalimab

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the two proprietary candidate drugs, ATOR-1017...


Sep 28, 2020, 07:24 ET Alligator Bioscience appoints Gayle Mills as Chief Business Officer

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today the appointment of Gayle Mills as Chief Business Officer to lead the company's...


Sep 24, 2020, 10:58 ET Alligator Bioscience launches a new immuno-oncology concept

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept for patient specific immunotherapy, called...


Sep 16, 2020, 02:39 ET Alligator Bioscience receives patent approval for the drug candidate ATOR-1015

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No....


Sep 09, 2020, 08:17 ET Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months delay for the planned Phase Ib study with...


Sep 04, 2020, 02:41 ET Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate...


Aug 27, 2020, 02:49 ET Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical Phase I study of the drug candidate...


Aug 25, 2020, 05:56 ET Alligator Bioscience Virtual R&D Day - August 27, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) invites to a virtual R&D Day on August 27 at 2:00 p.m. - 3:00 p.m., in which CEO Per Norlén and COO...


Aug 25, 2020, 05:09 ET Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020

Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug...


Jul 13, 2020, 07:24 ET Alligator Bioscience AB (publ) Interim Report January-June 2020

Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator's clinical development ...


Jun 15, 2020, 05:31 ET Alligator Bioscience Appoints New CFO

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the appointment of Marie Svensson as Chief Financial Officer, CFO. Marie Svensson has...


Jun 10, 2020, 09:37 ET Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...


Jun 04, 2020, 08:12 ET Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology

Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced signing of a collaboration agreement. ...


Jun 01, 2020, 07:47 ET Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 million in a second installment of...


May 29, 2020, 08:12 ET Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data from the ongoing Phase I clinical...


Apr 27, 2020, 00:21 ET Alligator Bioscience Presents Promising Interim Phase I Data for its Bispecific Drug Candidate ATOR-1015 at AACR

Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the ongoing Phase I clinical trial with the...


Apr 23, 2020, 02:29 ET Alligator Bioscience AB (publ) Interim Report January-March 2020

Stronger focus on clinical projects "The focusing of our operations protects the company's liquidity, but is also part of our long-term strategy with ...


Apr 20, 2020, 07:14 ET Alligator Bioscience's Board of Directors Reduces its Fees and Offers Possibility for Postal Voting in Front of the Annual General Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company's Nomination Committee, following an initiative from all members of...


Apr 07, 2020, 03:26 ET Alligator Bioscience Increases Focus on Clinical Development

Alligator Bioscience (Nasdaq Stockholm: ATORX) , announced today that the company has decided to increase its focus on the clinical development...


Apr 01, 2020, 04:29 ET Alligator Bioscience Informs About Temporary Halt of Recruitment of New Patients due to the COVID-19 Pandemic

Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new patients to the company's ongoing Phase I...


Mar 31, 2020, 03:48 ET Notice of Annual General Meeting in Alligator Bioscience AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text...


Mar 05, 2020, 08:01 ET Alligator Bioscience Appoints Andreas Johannesson as interim Chief Financial Officer

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The...


Mar 02, 2020, 04:40 ET Alligator Bioscience's Annual Report 2019 Published

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


Feb 12, 2020, 02:20 ET Alligator Bioscience AB Year-end Report January-December 2019

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at...